Statements (72)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:DNA
|
| gptkbp:associated_with |
gptkb:Oncology
gptkb:ALK-positive_lung_cancer molecular diagnostics therapeutic interventions survival rates targeted therapy clinical outcomes therapeutic efficacy cancer therapies clinical implications diagnostic challenges clinical management molecular profiling resistance to chemotherapy clinical trials outcomes immunotherapy response EGFR mutations molecular alterations |
| gptkbp:can_detect |
FISH analysis
|
| gptkbp:cause |
oncogenic signaling
|
| gptkbp:discovered_by |
gptkb:2007
|
| gptkbp:exhibits |
tyrosine kinase activity
|
| https://www.w3.org/2000/01/rdf-schema#label |
EML4-ALK fusion gene
|
| gptkbp:influences |
patient outcomes
therapeutic strategies treatment efficacy treatment response treatment decisions patient management research directions |
| gptkbp:involves |
gptkb:ALK_gene
gptkb:EML4_gene gptkb:fusion chromosomal abnormalities protein-protein interactions molecular mechanisms gene rearrangement chromosomal rearrangement genetic alterations oncogenic fusion |
| gptkbp:is_found_in |
cancer research
genetic research genomic studies oncology research tumor samples pathological studies lung tissue biopsy specimens |
| gptkbp:is_linked_to |
biomarker discovery
personalized medicine tumor heterogeneity adverse effects cancer progression specific biomarkers therapeutic targets poor prognosis therapeutic resistance cancer treatment strategies treatment resistance cancer biomarkers increased metastasis clinical features molecular targets patient outcomes variability |
| gptkbp:is_often_seen_in |
gptkb:Oncology
|
| gptkbp:is_recognized_by |
clinical trials
genetic testing |
| gptkbp:is_targeted_at |
ALK inhibitors
|
| gptkbp:resulted_in |
abnormal cell growth
|
| gptkbp:bfsParent |
gptkb:EML4
|
| gptkbp:bfsLayer |
7
|